BSG005

Phase 2Small molecule

BBiosergen AS

BSG005 is one of 3 small molecule programs targeting Invasive Fungal Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Invasive Fungal InfectionRecruiting

Invasive Fungal InfectionPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Invasive Fungal Infection

#DrugCompanyPhaseTrials

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 2

Posaconazole IV

Merck & Co.

Phase 2

1 3

BSG005

BBiosergen AS

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Invasive Fungal Infection1 trial

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection

Recruiting·BBiosergen AS·Phase 1/2·NCT06678113·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BSG005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BSG005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BSG005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biosergen AS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiosergen AS

BSG005

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Invasive Fungal Infection1 trial

References

Drug Info

Quick Facts

Related News